Company profile
AbbVie
Immunology
Share price · ABBV
$258.92+49.51 (+23.64%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(46 total)
46Total Assets
11Approved
9Phase 3 / Filed
26Phase 1–2 / Early
18Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
adalimumab(Humira) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseaseAtherosclerotic Cardiovascular DiseaseAtopic DermatitisPsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
Cariprazine (Vraylar)(Vraylar) | Approved | Dopamine D3/D2 receptor (partial agonist)Small molecule | Major Depressive DisorderSchizophrenia |
Divalproex sodium (Depakote)(Depakote) | Approved | GABAergic neurotransmissionSmall molecule | Epilepsy |
| Approved | SLAMF7 (CS1/CD319)Monoclonal antibody | Multiple Myeloma | |
foslevodopa/foscarbidopa(Vyalev) | Approved | dopamine precursorSmall molecule | Parkinson's Disease |
| Approved | dopamine precursorSmall molecule | Parkinson's Disease | |
risankizumab(Skyrizi) | Approved | IL-23 p19Monoclonal antibody | Inflammatory Bowel DiseaseAtopic DermatitisPsoriasis Ulcerative Colitis, Crohn's Disease |
| Approved | METAntibody–drug conjugate | Non-Small Cell Lung Cancer | |
upadacitinib(Rinvoq) | Approved | JAK · JAK1Small molecule | Inflammatory Bowel DiseaseAtopic DermatitisSystemic Lupus ErythematosusRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease |
| Approved | GABAergic neurotransmissionSmall molecule | Epilepsy | |
| Phase 3 | VEGF-AGene therapy / editing | Age-Related Macular Degeneration | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | Muscarinic M4 receptorSmall molecule | Alzheimer's DiseaseSchizophrenia | |
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.